Frontiers in Oncology (May 2019)
Consensus Report From the Miami Liver Proton Therapy Conference
- Michael D. Chuong,
- Adeel Kaiser,
- Fazal Khan,
- Parag Parikh,
- Edgar Ben-Josef,
- Christopher Crane,
- Thomas Brunner,
- Toshiyuki Okumura,
- Niek Schreuder,
- Søren M. Bentzen,
- Alonso Gutierrez,
- Alejandra Mendez Romero,
- Alejandra Mendez Romero,
- Sang Min Yoon,
- Navesh Sharma,
- Tae Hyun Kim,
- Kazushi Kishi,
- Fred Moeslein,
- Sarah Hoffe,
- Tracey Schefter,
- Steven Hanish,
- Marta Scorsetti,
- Smith Apisarnthanarax
Affiliations
- Michael D. Chuong
- Baptist Hospital of Miami, Miami Cancer Institute, Miami, FL, United States
- Adeel Kaiser
- University of Maryland Medical Center, Baltimore, MD, United States
- Fazal Khan
- Baptist Hospital of Miami, Miami Cancer Institute, Miami, FL, United States
- Parag Parikh
- Henry Ford Health System, Detroit, MI, United States
- Edgar Ben-Josef
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States
- Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Thomas Brunner
- Freiburg University Medical Center, Freiburg, Germany
- Toshiyuki Okumura
- Department of Radiation Oncology, University of Tsukuba, Tsukuba, Japan
- Niek Schreuder
- Provision CARES Proton Therapy, Knoxville, TN, United States
- Søren M. Bentzen
- University of Maryland Medical Center, Baltimore, MD, United States
- Alonso Gutierrez
- Baptist Hospital of Miami, Miami Cancer Institute, Miami, FL, United States
- Alejandra Mendez Romero
- Erasmus Medical Center, Erasmus University Rotterdam, Rotterdam, Netherlands
- Alejandra Mendez Romero
- 0Holland Proton Treatment Center, Rotterdam, Netherlands
- Sang Min Yoon
- 1Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
- Navesh Sharma
- 2Department of Radiation Oncology, Pennsylvania State University, University Park, PA, United States
- Tae Hyun Kim
- 3National Cancer Center, Goyang-si, South Korea
- Kazushi Kishi
- 4Hokkaido Hospital, Sapporo, Japan
- Fred Moeslein
- 5Sarasota Memorial Hospital, Sarasota, FL, United States
- Sarah Hoffe
- 6Moffitt Cancer Center, Tampa, FL, United States
- Tracey Schefter
- 7University of Colorado Anschutz Medical Campus, Aurora, CO, United States
- Steven Hanish
- University of Maryland Medical Center, Baltimore, MD, United States
- Marta Scorsetti
- 8Department of Radiation Oncology, Humanitas University, Rozzano, Italy
- Smith Apisarnthanarax
- 9Department of Radiation Oncology, University of Washington, Seattle, WA, United States
- DOI
- https://doi.org/10.3389/fonc.2019.00457
- Journal volume & issue
-
Vol. 9
Abstract
An international group of 22 liver cancer experts from 18 institutions met in Miami, Florida to discuss the optimal utilization of proton beam therapy (PBT) for primary and metastatic liver cancer. There was consensus that PBT may be preferred for liver cancer patients expected to have a suboptimal therapeutic ratio from XRT, but that PBT should not be preferred for all patients. Various clinical scenarios demonstrating appropriateness of PBT vs. XRT were reviewed.
Keywords
